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Abstract
Background: Malignant glioma cell line models are integral to pre-clinical testing of novel potential therapies.
Accurate prediction of likely efficacy in the clinic requires that these models are reliable and consistent. We assessed
this by examining the reporting of experimental conditions and sensitivity to temozolomide in glioma cells lines.
Methods: We searched Medline and Embase (Jan 1994-Jan 2021) for studies evaluating the effect of temozolomide
monotherapy on cell viability of at least one malignant glioma cell line. Key data items included type of cell lines,
temozolomide exposure duration in hours (hr), and cell viability measure (IC50).
Results: We included 212 studies from 2789 non-duplicate records that reported 248 distinct cell lines. The
commonest cell line was U87 (60.4%). Only 10.4% studies used a patient-derived cell line. The proportion of studies not
reporting each experimental condition ranged from 8.0–27.4%, including base medium (8.0%), serum supplementation
(9.9%) and number of replicates (27.4%). In studies reporting IC50, the median value for U87 at 24 h, 48 h and 72 h was
123.9 μM (IQR 75.3–277.7 μM), 223.1 μM (IQR 92.0–590.1 μM) and 230.0 μM (IQR 34.1–650.0 μM), respectively. The
median IC50 at 72 h for patient-derived cell lines was 220 μM (IQR 81.1–800.0 μM).
Conclusion: Temozolomide sensitivity reported in comparable studies was not consistent between or within
malignant glioma cell lines. Drug discovery science performed on these models cannot reliably inform clinical
translation. A consensus model of reporting can maximise reproducibility and consistency among in vitro studies.
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Introduction
Malignant glioma is the most common primary cancer
of the central nervous system [1]. Treatment options
vary between types of malignant glioma, but prognosis is
poor [2]. Classification depends on histological and mo-
lecular features [3]. Glioblastoma, accounting for 60% of
all malignant gliomas, carries the worst outcome with
median survival of 6–8 months and 3% 5-year survival
[2, 4, 5]. Standard care has not changed in 15 years and
involves surgical resection followed by a combination of
radiotherapy and chemotherapy with the alkylating agent
temozolomide [6]. No human clinical trials to date have
demonstrated superior treatment effect with a novel
therapeutic agent [7], so there is an urgent need to
examine the processes of drug discovery.
Cancer drug discovery utilises pre-clinical models to
predict the likely effect of a novel compound on cancer
tissue. In vitro cell cultures are readily available from
repositories [8] and in studies of malignant glioma, tem-
ozolomide is frequently used as the comparative
therapeutic agent because of its role in standard care.
The robustness of this strategy depends on the reproduci-
bility of temozolomide sensitivity in vitro, which may be
affected by variations in experimental conditions [9, 10].
This is critical to experimental design and to data inter-
pretation, so requires adequate reporting.
Transparency in clinical research has received increas-
ing attention in the past two decades. There has been an
expansion of reporting guidelines for clinical studies fa-
cilitated by the Enhancing the Quality and Transparency
Of health Research (EQUATOR) network [11]. Most
guidelines relate to clinical research, but the Animal Re-
search: Reporting of In Vivo Experiments (ARRIVE)
guidelines are relevant to pre-clinical animal models
[12]. However, there are currently no standardised
reporting guidelines for cell culture studies. Evaluation
of the experimental conditions and drug sensitivity of
cell lines in published reports may provide an insight
into the reproducibility and consistency in these models.
The aim of this review was to quantify the variability
and reporting of experimental conditions in in vitro
studies using malignant glioma cell lines and to assess
variations in temozolomide sensitivity.
Methods
There is no suitable repository for systematic review of
in vitro studies in which our protocol could be regis-
tered. We followed the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA)
guidelines.
Eligibility criteria
We included studies published after 1993 that evaluated
the effect of temozolomide monotherapy on cell viability
of at least one malignant glioma cell line. The evaluation
of temozolomide could be a control experiment within a
study. There was no limit on the type of cell viability
measure. We excluded studies that utilised a drug-
resistant cell line, a modified preparation of temozolo-
mide, or an animal model. Studies using cell line-based
xenotransplant animal models or reporting outcome
measures other than cell viability were excluded.
Information sources
We searched Ovid Medline and Embase between Janu-
ary 1994 and January 2021 using a combination of
search terms relating to gliomas, cell lines, temozolo-
mide, and cell death. The full search strategies are avail-
able in Supplementary Material. Our search date was on
28th January 2021. There was no hand search or search
in the grey literature.
Study selection & data extraction
The online tool Covidence was our platform for con-
ducting the primary screening and data extraction in this
review. We applied the built-in deduplication function
on the platform to records retrieved from our database
search. One reviewer (MB) screened titles and abstracts
of all records, of which 10% excluded records were
reviewed by a second reviewer (MTCP). We used the
same review approach for full-text eligibility assessment.
One reviewer (MB) extracted data from all eligible arti-
cles and a second reviewer (MTCP) independently ex-
tract data from 40% of these studies. We resolved
disagreements by discussion between the two reviewers
or by seeking resolution from a third reviewer (PMB).
Data items
We collected data on study characteristics, experimental
setup and cell viability measures. Study characteristics
included year of publication, country of primary affili-
ation, the primary aim of study, and types of cell lines
used. ‘Primary aim of study’ had three categories: “thera-
peutic evaluation” referred to studies comparing the ef-
fects on cell lines of another therapeutic agent alone
against temozolomide; “pathway modification” referred
to studies that altered cellular pathways with a
molecularly targeted compound and assessed the effect
of temozolomide on the cell lines; “gene or protein
measurement” referred to studies that measured levels
of molecular markers in response to temozolomide. We
categorised cell lines into human cell lines, murine cell
lines, and cancer stem cell-like patient-derived cell lines.
Patient-derived cell lines were developed from patients
with malignant glioma at the investigators’ institute. Ex-
perimental setup data included temozolomide concen-
tration, temozolomide exposure duration, base medium,
addition of serum, cell density, cell passage number, use
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of hypoxic environment, and temperature and percent-
age of carbon dioxide in the ambient incubator
environment.
Cell viability was our outcome of interest. Data on cell
viability included the assay, quantification technique
used and cell viability measurement. Cell viability assays
included 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyl-2H-
tetrazolium bromide (MTT), sulphondamine B (SRB),
annexin V, propium iodide (PI), trypan blue, bromo-
deoxyuridine (BrdU) and luciferase-based techniques.
Quantification techniques included flow cytometry, col-
orimetric or fluorometric plate reader, microscopy with
manual counting, and microscopy with automated
counting. Where reported, we collected drug sensitivity
measures on half-maximal inhibitory concentration
(IC50), half-maximal effective concentration (EC50), dose
reduces initial population to 10% (LD10), dose reduces
survival number of cells to 37% (D37), approximate con-
centration of drug tolerated without lethality (DT), and
median-effect dose (Dm). To assess the internal validity,
we assessed whether a study reported the number of
replicate plates and the number of replicates per plate.
Risk of bias
There was no suitable risk of bias tool for the type of
studies included in this review. The completeness of
reporting of the data items described above was instead
used to indicate the transparency of the studies to
permit summarisation of comparable studies.
Data synthesis
We used descriptive statistics to summarise the data
items. Our reporting of temozolomide sensitivity mea-
sures was stratified for the two most common cell lines
(U87, U251) and patient-derived cell lines. We divided
studies into groups that had the same cell lines exposed
to temozolomide for the same duration, in a non-
hypoxic environment, and reported the same drug sensi-
tivity measures. We tested the homogeneity of variances
in temozolomide sensitivity across cell lines using
Levene’s and Fligner-Killeen tests. There was no plan for
meta-analysis because studies were anticipated to be het-
erogeneous and drug sensitivity measures without a
measure of variance are not amenable to meta-analysis.
These reasons also precluded the assessment of report-
ing bias. We performed all analyses in R version 4.1.0
using ‘tidyverse’ (v1.3.1), ‘gtsummary’ (v1.4.1), and ‘car’
(v.3.0–10) packages.
Results
Study selection and characteristics
Our search retrieved 3586 records. After removing 797
duplicates, 2789 records underwent title and abstract
screening, of which 1532 studies had full-text eligibility
assessment. We included 212 eligible studiess1–213 using
malignant glioma cell lines that reported cell viability
measures associated with temozolomide (Fig. 1). Of the
1320 studies excluded at full eligibility assessment, the
primary reason for exclusion for 717 studies was no
reporting of cell viability measures.
Of all the included studies, 140 (66.0%) were published
in or after 2015. Countries accounting for over 10% of
the included studies were China (35.4%) and the United
States (17.9%). The proportion of studies published in or
after 2015 from China and from the United States was
78.9 and 57.9%, respectively. Most studies (85.4%) evalu-
ated therapeutic agents against temozolomide in their
cell lines as the primary aim. There were 19 (9.0%) stud-
ies measuring gene or protein levels in their cell lines in
response to temozolomide and 12 (5.6%) studies
assessed the cell line response to temozolomide after
modification of a cellular pathway. A human glioma cell
line was at least one of the cell lines used in 193 (91.0%)
studies. Twenty-three (10.8%) studies used at least one
murine cell line and 22 (10.4%) studies used at least one
patient-derived cell line (Table 1). Most studies (77.4%)
used two or more cell lines in their studies.
Cell lines & experimental setup
Of 750 cell lines reported in the 212 included studies,
there were 248 distinct cell lines. The three most used
cell lines were U87 (60.4%), U251 (41.0%), and T98G
(26.4%). Their use did not appear to change over time
(Table 1). Patient-derived cell lines were used in 7.8%
studies published in 2018 or after compared with over
12.5% in studies published before 2015. There were 130
distinct patient-derived cell lines reported in 22 studies.
Dulbecco’s Modified Eagle Medium (DMEM) was the
commonest base medium, used in 142 (66.5%) studies
(Table 2). There were 23 (10.8%) studies that used a cus-
tomised medium and 17 (8.0%) studies did not report
the type of base medium used. Reporting of carbon diox-
ide concentration and temperature was missing in 54
(25.5%) and 52 (24.5%) studies, respectively. Five (2.3%)
studies utilised a hypoxic environment, but 54 (25.5%)
studies did not report the oxygen specification. Cell
density was frequently reported in 154 (72.6%) studies.
Cell passage number was reported in only 16 (7.5%)
studies.
Specification of temozolomide use
The range of temozolomide concentrations used in de-
termining drug sensitivity was not determinable from 30
(14.2%) studies (Table 3). The median lower limit of
temozolomide concentration was 0.1 μM (range 0–
6250 μM, interquartile range [IQR] 0-10 μM) and the
median upper limit was 800 μM (range 30–400,000 μM,
IQR 250–1266 μM). A single temozolomide exposure
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time was not reported in 47 (22.2%) studies, of which 38
studies instead reported a range of exposure times. The
three most common temozolomide exposure times were
72 h (29.1%), 48 h (16.7%), and 24 h (11.8%).
Cell viability methods and drug sensitivity measures
MTT was the most common primary cell viability assay,
which was used in 95 (44.8%) studies (Table 3). Thirty-five
(16.5%) studies used the Cell Counting Kit-8, another col-
orimetric assay. Five (2.4%) studies did not specify their
cell viability assays. A plate reader was used in 124 (58.5%)
studies and 45 (21.2%) studies did not specify their quanti-
fication techniques for measuring cell viability. Among
our pre-specified drug sensitivity measures, 182 (85.8%)
studies reported IC50 of temozolomide for their cell lines.
The other drug sensitivity measures each had fewer than
10 studies reporting them.
Temozolomide sensitivity
We examined studies together that used the same
temozolomide exposure time and reported IC50 of
temozolomide for their cell lines (Fig. 2). Descriptive
statistics here relate to cell lines at each exposure
duration that had ≥10 measurements of temozolo-
mide IC50. The median IC50 of temozolomide for
U87 cell line at 24 h, 48 h and 72 h was 123.9 μM
(IQR 75.3–277.7 μM), 223.1 μM (IQR 92.0–590.1 μM)
and 230.0 μM (IQR 34.1–650.0 μM), respectively (Fig.
2A). In U251 cell line, the median temozolomide
IC50 at 48 h and 72 h was 240.0 μM (IQR 34.0–
338.5 μM) and 176.50 μM (IQR 30.0–470.0 μM), re-
spectively. The median IC50 of temozolomide at 72 h
for T98G and patient-derived cell lines was 438.3 μM
(IQR 232.4–649.5 μM) and 220 μM (IQR 81.1–
800.0 μM), respectively.
Fig. 1 Flowchart describing study selection for inclusion
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The asymmetrical distribution of the IC50 values dem-
onstrated in Fig. 2A may be caused by the differing ex-
perimental conditions. To examine for the source(s) of
this variation in IC50, we then included studies that used
a normoxic culture environment (excluding hypoxic cul-
ture condition) and that used MTT as the cell viability
assay, the most common composite conditions. The IC50
was 155.1 μM (IQR 37.8–640.5 μM) for U251 cell line at
48 h and 230.0 μM (IQR 58.0–650.0 μM) for U87 cell
line at 72 h (Fig. 2B), compared to 240.0 μM and
230.0 μM in the previous analysis of U251 and U87, re-
spectively, at the same time points. The interquartile
ranges of the IC50 from more homogeneous studies and
from unrestricted studies were similar. Tests for homo-
geneity did not demonstrate evidence of a difference in
IC50 variances across cell lines exposed to temozolomide
for 72 h (Levene’s test: p = 0.237; Fligner-Killeen test:
p = 0.346).
Discussion
This systematic review identified 213 studies using cell
culture models of malignant gliomas reporting drug
sensitivity to temozolomide. Over 700 studies were
excluded because they did not report cell viability
measures. There were a wide variety of cell lines, and we
did not observe an increase over time in patient-derived
cell lines despite the implications of the cancer stem cell
hypothesis for glioma biology. The reporting of experi-
mental conditions and temozolomide specifications were
variable, which made interpretation difficult. Temozolo-
mide sensitivity was not consistent within each cell line.
Furthermore, the range of concentrations used across
the selected publications is not physiologically or clinic-
ally relevant to glioblastoma treatment (approximately
30-50uM in tumour and plasma [13]). This has implica-
tions for conduct and interpretation of drug discovery.
Sampling variation of temozolomide sensitivity in the
same cell lines between studies should produce a symmet-
rical distribution of IC50 around the median. The asym-
metrical distributions of IC50 in each cell line (Fig. 2A)
suggested additional contributors to inconsistency other
than sampling variations. While further matching of ex-
perimental conditions (Fig. 2B) reduced the asymmetry,
the residual asymmetry indicated that inconsistency re-
sulted from differences in unmeasured experimental condi-
tions and in cell behaviours in each cell line. Issues with
cultured malignant glioma cell lines are not new. Serum
supplementation in classic cell lines has been shown to in-
duce astrocytic differentiation resulting in transcriptional
and epigenomic changes that do not reflect the human dis-
ease [14, 15]. There are further problems with misidentifi-
cation and cross-contamination [16, 17]. These limitations










Type of cell line
Human glioma cell line(s) 193 (91.1%) 65 (90.3%) 57 (90.5%) 71 (92.2%)
Murine glioma cell line(s) 23 (10.8%) 5 (6.9%) 6 (9.5%) 12 (15.4%)
Patient-derived cell line(s) 22 (10.4%) 9 (12.5%) 7 (11.1%) 6 (7.7%)
Number of cell lines used
One 48 (22.6%) 14 (19.4%) 15 (23.8%) 19 (24.7%)
Two 74 (34.9%) 19 (26.4%) 26 (41.3%) 29 (37.7%)
Three or more 90 (42.5%) 39 (54.2%) 22 (34.9%) 29 (37.7%)
Ten commonest cell lines
U87 129 (60.4%) 47 (65.3%) 37 (58.7%) 44 (57.1%)
U251 87 (41.0%) 24 (33.3%) 31 (49.2%) 33 (41.6%)
T98G 56 (26.4%) 25 (34.7%) 11 (17.5%) 20 (26.0%)
A172 29 (13.7%) 8 (11.1%) 11 (17.5%) 10 (13.0%)
U373 27 (12.7%) 15 (20.8%) 6 (9.5%) 6 (7.8%)
U138 26 (12.3%) 15 (20.8%) 6 (9.5%) 5 (6.5%)
LN229 22 (10.4%) 7 (9.7%) 4 (6.3%) 11 (14.3%)
C6 20 (9.4%) 5 (6.9%) 6 (9.5%) 9 (11.7%)
LN18 13 (6.6%) 6 (8.3%) 2 (3.2%) 5 (6.5%)
U118 14 (6.6%) 5 (6.9%) 5 (7.9%) 4 (5.2%)
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can contribute to an explanation of our findings of cell
lines having inconsistent temozolomide sensitivity. Drug
discovery science performed on these incomparable and
nonrepresentative malignant glioma models cannot reliably
inform clinical translation.
Although there was no apparent increase in its use,
about a quarter of the included studies used patient-
derived glioma cell lines, so-called stem-like cancer cells.
The purported advantage of these cell is their ability to
retain genetics and transcriptional characteristics of the
human disease better than standard serum grown hu-
man cell lines [14, 18, 19]. Examining the effect of novel
compounds on these stem-like cells may be more clinic-
ally relevant. However, there was no evidence of a
smaller (or larger) variance of temozolomide sensitivity
compared with other human cell lines. Better under-
standing of the molecular characteristics of tumour cells
as well as experimental conditions in studies using
patient-derived cell lines can increase comparability and
reproducibility between studies. Initiatives that offer mo-
lecularly defined and clinically representative patient-
derived cell lines such as The Human Glioblastoma Cell
Culture resource [20] could facilitate more reproducible
drug screening.
One of the challenges in summarising temozolomide
sensitivities from the included studies was the subopti-
mal reporting of key experimental conditions. These
conditions, such as cell density and carbon dioxide
levels, can affect the accuracy of cell viability assay read-
out [21]. Guidelines for the conduct of using cell lines
for biomedical research [22] relate to best practice in the
standard operating procedure within each laboratory.
While some aspects of these guidelines are relevant to
Table 2 Experimental design of 212 included studies
Characteristics N = 212
Base medium
DMEM 141 (66.5%)
Customised media 23 (10.8%)




















Cell density 154 (72.6%)
Number of cell passage 16 (7.5%)
Number of replicates 58 (27.4%)
Number of plate replicates 42 (19.8%)
DMEM Dulbecco’s Modified Eagle Medium, DMEM/F12 Dulbecco's Modified
Eagle Medium/Nutrient Mixture F-12
Table 3 Temozolomide specification and methods for
measuring cell viability
Characteristics N = 212
Temozolomide concentration (μM)
Lower range (IQR)a 0 (0-10)
Upper range (IQR)a 800 (250.0-1266)
Unspecified 30 (14.2%)
Temozolomide exposure time
<24 hours 8 (3.8%)
24 hours 24 (11.3%)
48 hours 34 (16.0%)
72 hours 59 (27.8%)
96 hours 15 (7.1%)
>96 hours 25 (11.8%)






Trypan blue 11 (5.2%)
Other 55 (25.9%)
Unspecified 5 (2.4%)
Method for cell viability quantification
Plate reader 124 (58.5%)
Flow cytometry 13 (6.1%)
Microscopy and manual counting 11 (5.2%)
Microscopy and automated counting 3 (1.4%)
Technique in a reference/manual 16 (7.5 %)
Unspecified 45 (21.2%)
aRange of temozolomide used to assess drug sensitivity was reported in
183 studies.
IQR interquartile range, MTT 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyl-2H-
tetrazolium bromide, CCK-8 Cell Counting Kit-8, MTS MTT with
phenazine methosulfate
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the consistency of cancer cell line behaviours, they do
not provide a framework for reporting experimental
conditions that could affect compound sensitivity. In
clinical research, the EQUATOR network has facilitated
the development of tailored reporting guidelines specific
to different study designs. The earliest guideline was the
Consolidated Standards of Reporting Trials (CONSORT)
statement [23], which has been cited for over 8000 times
since its first version published 25 years ago [24]. The
conception of this guideline stemmed from a unanimous
opinion from a group of clinical research experts that
the quality of reports of randomised controlled trials was
in adequate. Our findings from malignant glioma cell
line studies indicate similar concerns about the reporting
quality in drug discovery studies using cancer cell lines.
Variations in experimental design may not be fully cap-
tured in a standardised reporting guideline. However,
without reproducibility and predictability, data interpret-
ation is unreliable. The issue of reproducibility in pre-
clinical animal models that drove the development of
ARRIVE guidelines [12]. What we have in cell line stud-
ies should prompt development of guidelines for trans-
parency, consistency and reproducibility.
Strengths and limitations
This systematic review had a comprehensive search that
included all malignant glioma cell lines with their re-
spective drug sensitivity to temozolomide. The vast
number of cell lines summarised provided an overview
of in vitro studies investigating malignant gliomas. Find-
ings of our review also described the methodological
practice and reporting associated with the assessment of
cell viability to therapeutic agents. All these are import-
ant considerations for better design comparable studies
in the future.
We drew our results only from malignant glioma cell
line models. There are other related experimental
models such as drug resistant cell lines, genetically
modified cell lines, tumour spheres, organoids and xeno-
transplant models [10]. Our findings are likely to be rele-
vant and generalisable to other models because sources
of heterogeneity remain uncontrolled and there are more
margins of errors associated with other experimental
models. The need for consistency and reproducibility
apply to all models. There may be other cellular or ex-
perimental features that affect cell viability that were not
assessed here. These may include MGMT promoter
Fig. 2 Temozolomide sensitivity measured by half-maximal inhibitory concentration (IC50) in different cell lines stratified by temozolomide
exposure time. (A) IC50 summarised for cell lines that had at least 10 measurements reported in the included studies at the specified exposure
time. Tests for homogeneity of variances showed no evidence of a difference between cell lines at 72 h (Levene’s test: p = 0.249; Fligner-Killeen
test: p = 0.389). References for these studies are: U87 at 24 h,s9 s21 s26 s56 s57 s60 s83 s91 s105 s120 s146 s209 U87 at 48 h,s31 s58 s67 s88 s96 s109 s112 s114 s121
s156 s160 s163 s189 s197 s205 s209 s211 U251 at 48 h,s17 s44 s29 s31 s58 s67 s88 s96 s99 s109 s112 s114 s116 s149 s152 s156 s175 s184 s186 s187 s189 s197 s211 U87 at 72 h,s7
s13 s14 s48 s50 s63 s94 s97 s98 s104 s106 s128 s130 s134 s135 s137 s138 s145 s154 s158 s166 s169 s174 s195 s196 s198 s200 s203 s212 U251 at 72 h,s2 s30 s37 s46 s59 s97 s125
s131 s134 s135 s145 s154 s166 s167 s174 s181 s185 s196 s200 s203 s212 T98G at 72 h,s2 s28 s46 s48 s63 s94 s145 s166 s167 s192 s196 s200 and patient-derived cell lines at
72 h.s14 s122 s123 s127. (B) Further restricting to studies that did not use a hypoxic environment and quantified cell viability using MTT. Exposure
time in hours is shown on the top panel. IC50 = half-maximal inhibitory concentration. References for these studies are: U251 at 48 h
s31 s44 s58 s96
s149 s152 s156 s175 s187 s189 and U87 at 72 hs7 s13 s98 s106 s128 s130 s134 s137 s145 s166 s195 s200 s212
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methylation, isocitrate dehydrogenase (IDH) mutations,
telomerase reverse transcriptase (TERT) mutations, 1p/
19q co-deletion and alpha-thalassemia mental retard-
ation syndrome (ATRX) mutations [25]. While it would
be useful to summarise, there is little consistent evidence
to support their role in cell viability and they are very
unlikely to be reported in non-patient-derived cell lines.
These specific mutations are unlikely to contribute to
the observed variability in classical cell lines which
should each, in theory, share the same genetic back-
ground, although other genetic and epigenetic changes
may have been acquired in culture over time [26]. Stud-
ies using patient-derived cell lines often reported patient
characteristics, which could partially explain the drug
sensitivity variations observed. These cell lines are more
likely to be glioma stem cell lines, which are more
heterogeneous. The small number of cell lines with com-
parable experimental conditions would prevent mean-
ingful subgroup analyses to investigate additional the
effect of additional characteristics on cell viability.
Conclusions
Temozolomide sensitivity reported in comparable stud-
ies was not consistent between and within individual
malignant glioma cell lines. This raises concerns about
the reliability and translational value of drug discovery
studies that use glioma cell lines. Appraisal and inter-
pretation of the results can only be achievable if studies
report key experimental conditions. While there will be
variations of opinion on what the optimal design is, a
consensus model of a reporting structure is the only ra-
tional way to maximise the yield from in vitro studies to
find novel therapies for our patients.
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